“I am adamant about being involved and engaged with companies that want to change how care is accessed, financed, and delivered,” said Dr. Edwards.
CHICAGO (PRWEB) April 18, 2023
CancerIQ, the platform powering early cancer detection and prevention across broad patient populations, today announced Carladenise Edwards, PhD, a dedicated leader with more than three decades of experience in healthcare, government and technology, as the newest member of its board of directors.
Dr. Edwards has led strategy at several large health systems, including serving as the chief strategy officer of Henry Ford Health System, Providence St. Joseph Health, and Alameda Health System at various points throughout her career.
“Carladenise’s firsthand experience delivering results and exceeding growth targets for large health systems makes her an invaluable addition to CancerIQ’s board,” said Feyi Ayodele, CEO and co-founder of CancerIQ. “I am personally inspired by Carladenise, and I’m thrilled that CancerIQ’s customers can benefit from her expertise and passion.”
Transitioning away from the health system C-suite, Dr. Edwards now serves as strategic advisor and board member for well-established healthcare companies such as Clover Health and Heluna Health. She joined CancerIQ’s board because the Series B startup aligns with her personal mission.
“I am adamant about being involved and engaged with companies that want to change how care is accessed, financed, and delivered,” said Dr. Edwards. “CancerIQ was founded to democratize access to preventive oncology, so everyone — regardless of race or socioeconomic class — can have the best chance of evading this devastating disease. This falls directly into my wheelhouse of priorities.”
Another facet of Dr. Edwards’ personal mission is to support the next generation of women leaders in healthcare, like CancerIQ’s CEO Feyi Ayodele.
“I personally have a commitment to supporting women, particularly Black women, who are working in the healthcare space,” Dr. Edwards said. “I’ve benefitted from people pushing me forward, and I am now dedicated to doing that for others.”
Dr. Edwards adds health system experience to a board already made up of members with diverse professional backgrounds, including experts in pharmacy, IT, investing, and life sciences.
“We are thrilled to add Dr. Edwards and her expertise running large health systems with varying patient populations and closing care gaps to CancerIQ’s board,” said Joel Krikston, managing director of venture investment at Merck Global Health Innovation Fund and CancerIQ board member. “Her perspective will be invaluable as we work toward addressing health disparities and detecting cancer early.”
Dr. Edwards earned her PhD in medical sociology from the University of Florida and a master’s degree in education and psychological services and bachelor’s degree in sociology from the University of Pennsylvania.
CancerIQ is the only cancer-focused precision health platform that empowers healthcare providers to detect cancer earlier and prevent it altogether across all patient populations. Integrated directly into real-time EHR workflows, CancerIQ makes it easy to gather comprehensive patient data, automatically map it to the latest evidence-based guidelines, and expand access to personalized care plans, cutting-edge clinical solutions, and genomic innovations. Learn more at canceriq.com, follow CancerIQ on Twitter, LinkedIn or Facebook, and check out our latest eBook.